Cleveland BioLabs, Inc. (CBLI) stock is up 2.22% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With CBLI Stock Today?
Cleveland BioLabs, Inc. (CBLI) stock has fallen -11.54% while the S&P 500 is up 0.18% as of 9:59 AM on Wednesday, Jul 7. CBLI is down -$0.72 from the previous closing price of $6.24 on volume of 461,740 shares. Over the past year the S&P 500 is up 36.85% while CBLI is up 153.21%. CBLI lost -$0.18 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Cleveland BioLabs, Inc. click here.
More About Cleveland BioLabs, Inc.
Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in the mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for the prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug.
Click Here to get the full Stock Score Report on Cleveland BioLabs, Inc. (CBLI) Stock.
